LWP and lymphoma-related meetings and presentations

Slides:

Advertisements

Similar presentations

Follicular lymphoma Optimal primary therapy and consolidation ? Seminars in Hematological Oncology * Israel, April M. Dreyling, Dept. of Medicine.

Advertisements

8th Educational Course of the Lymphoma Working Party on "Lymphomas and Stem Cell Transplantation" October 2012 Bucharest, Romania

#EBMT2015 IEWP – EBMT 2015 Business Meeting Monday rd March 2015.

Novel Agents for Indolent Lymphoma and Mantle Cell Lymphoma Stephen Ansell, MD, PhD Mayo Clinic.

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides SUM10_1.ppt.

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2011 Summary Slides Worldwide SUM-WW11_1.ppt.

Treatment of Non- Hodgkin’s Lymphoma. Precursor B cell Lymphoblastic Leukemia Remission induction with combination therapy Consolidation phase: –High.

Treatment of B Cell Malignancies: Current and Emerging Strategies Thomas A. Rado, MD, PhD.

Optimizing Timing of Transplant in Hodgkin Lymphoma Ginna G. Laport, MD Associate Professor of Medicine Division of Blood & Marrow Transplantation Stanford.

(A) the hematopoietic stem cell transplanted (HSCT) recipients only (B) both autologous and allogeneic transplanted recipients (C) both solid organ and.

Low Grade Lymphomas: Treatment approaches Parameswaran Venugopal, MD Professor of Medicine Rush University Medical Center.

P Ferguson, R Hills, A Grech, L Kjeldsen, M Dennis, P Vyas, R Clark, N Russell, C Craddock, On behalf of the NCRI AML Working Group. An operational definition.

A new possible conditionning regimen before Autologous Stem Cell Transplantation for refractory high-grade lymphoma Z-BeEAM (Ibritumomab tiuxetan, Bendamustine,

Successful Treatment of Richter Transformation with Ibrutinib in a Patient with Chronic Lymphocytic Leukemia following Allogeneic Hematopoietic Stem Cell.

EBMT Activity Survey Teams Patients Transplants

Harrison CN et al. Proc ASH 2015;Abstract 59.

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.

Miguel-Angel Perales MD

Updates in Hodgkin Lymphoma

EBMT Activity Survey Teams 39,313 Patients 43,636 Transplants

EBMT Activity Survey Teams Patients Transplants

Biology of Blood and Marrow Transplantation

Treatment Decisions in Chemorefractory Follicular Lymphoma

Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma Taewoong Choi, Murali K. Kodali, Wen-Kai Weng

Chimerism-Based Pre-Emptive Immunotherapy with Fast Withdrawal of Immunosuppression and Donor Lymphocyte Infusions after Allogeneic Stem Cell Transplantation.

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION for MULTIPLE MYELOMA

Allogeneic Stem Cell Transplantation in Myelofibrosis

Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond.

Hematopoietic Stem Cell Transplantation for Refractory or Recurrent Non-Hodgkin Lymphoma in Children and Adolescents Thomas G. Gross, Gregory A. Hale,

Vascular Endothelial Growth Factor and Activin-A Serum Levels Following Allogeneic Hematopoietic Stem Cell Transplantation David Nachbaur, Petra Schumacher,

Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease–Guided Multiple DLIs Could Improve Outcomes.

Betty T. Tran, Abigail Halperin, Jason W. Chien

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Follicular Lymphoma: An Evidence-Based Review Denise M.

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Phase II Study of Risk-Adapted Therapy of Newly Diagnosed, Aggressive Non-Hodgkin Lymphoma Based on Midtreatment FDG-PET Scanning Yvette L. Kasamon,

Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced.

Controversies in Lymphoma: The Role of Hematopoietic Cell Transplantation for Mantle Cell Lymphoma and Peripheral T Cell Lymphoma Peter Dreger, Ginna.

Short title / Key scientific finding

Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation Vijaya.

Biology of Blood and Marrow Transplantation

Anas Younes, M.D. Memorial Sloan Kettering Cancer Center

Mitchell S. Cairo, Willi Woessmann, John Pagel

N.M.A. Blijlevens, J.P. Donnelly, B.E. de Pauw

Kasiani C. Myers, Stella M. Davies

Outcomes of Patients 65 Years and Older with Non-Hodgkin Lymphoma Receiving Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.

On Modeling Human Leukocyte Antigen–Identical Sibling Match Probability for Allogeneic Hematopoietic Cell Transplantation: Estimating the Need for an.

Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis Nicolas Novitzky, Valda.

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma John Kuruvilla, Gregory Pond, Richard.

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma Eric Smith, Sean M. Devlin, Satyajit.

Allogeneic Stem Cell Transplantation for Aplastic Anemia

Introduction. Title: Activities and Outcomes of Hematopoietic Cell Transplantation in Japan.

Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated.

Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic.

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-

C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Bridge to transplant following Bv+Bs regimen.

Yuri Fedoriw, T. Danielle Samulski, Allison M. Deal, Cherie H

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma.

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Pre-Transplant Comorbidity As an Outcome Predictor in Hematopoietic Cell Transplantation for Severe Aplastic Anemia SungNam Lim, Je-Hwan Lee, MD, PhD,

High Response Rate to Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Indolent Non-Hodgkin Lymphoma Adrian J.C. Bloor, Kirsty.

An algorithmic approach to FL

Mary Eapen Biology of Blood and Marrow Transplantation

How I treat acquired aplastic anemia

by Lapo Alinari, and Kristie A. Blum

Presentation transcript:

LWP and lymphoma-related meetings and presentations Lisbon 2018 #EBMT18

Lymphoma Working Party Activities Tuesday 20 March 2018, 07:00-09:00 –Room 3B EBMT LWP Open Research Forum Tuesday 20 March 2018, 11:00-12:30 - Auditorium II Lymphoma Working Party Session

Lymphoma Working Party Presentations Monday 19 March 2018, 09:00-10:30 – ORAL session- Auditorium VI A CONSENSUS PROJECT OF THE EBMT LYMPHOMA WORKING PARTY (LWP) /ECWM/ IWMF TO DEFINE INDICATIONS FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA. C Kyriakou EARLY EVENTS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH FOLLICULAR LYMPHOMA EXPOSED TO IDELALISIB: A SURVEY OF THE EBMT LYMPHOMA WORKING PARTY. L Sellner

Tuesday 20 March 2018– Poster Session ANALYSIS OF DATA COLLECTED IN THE EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION (EBMT) REGISTRY ON A COHORT OF PATIENTS WITH LYMPHOMA RECEIVING PLERIXAFOR. A Sureda CHECKPOINT INHIBITOR THERAPY FOR HODGKIN LYMPHOMA AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION: A RETROSPECTIVE ANALYSIS OF THE EBMT-LYMPHOMA WORKING PARTY. S Dietrich VARIATION IN THE USE OF STEM CELL TRANSPLANTATION IN THE MANAGEMENT OF FOLLICULAR LYMPHOMA (FL) AND INDOLENT LYMPHOMAS: A STUDY OF THE LYMPHOMA WORKING PARTY-EBMT. S Robinson

Other Lymphoma Related Presentations Educational Tuesday 20 March 2018, 09:00-10:30 The transplant algorithm in lymphoma- Auditorium I High-grade lymphoma. N Milpied, France Role of stem cell transplantation in patients with follicular lymphoma. S Montoto, UK Hodgkin disease. A Sureda, Spain Wednesday 21 March 2018, 11:00-12:30 - Pharmacologic pre-transplant interventions to enhance disease control – Room 3B Immune check-point inhibitors in lymphomas. MA Perales, US Workshop Monday 19 March 2018, 11:00-12:30- Haplo-identical transplantation versus other donor sources - Auditorium VIII Haplo-identical SCT in Hodgkin lymphoma. M Kwon, Spain Meet the expert Monday 19 March 2018, 08:00- 09:00 – Pavilion 4 Treatment of Richter syndrome. P Dreger, Germany Tuesday 20 March 2018, 08:00- 09:00 – Pavilion 4 Maintenance therapy in Hodgkin disease. A Sureda, Spain

Other Lymphoma Related Presentations Data Management Educational Session 2 Monday 19 March 2018 09:45-10:25 - Auditorium III Lymphoma- Med A-new drugs and treatment. S Montoto, UK Statistics Workshop Monday 19 March 2018 13:00-14:30 – Room 5C Survival curves: adjusted or not? A Boumendil, France/ S Montoto, UK Nurses Group Tuesday 20 March 2018, 17:00-18:00- Lymphoma - Room 3A Bridging therapies in lymphoma. S Robinson, UK The role of PET scan in lymphomas. V Vergote, Belgium Which transplant for which lymphoma. J Doorduijn, Netherlands

Follow us on Twitter @LymphomaWP_EBMT